Pharmaceutical PV DIV - FSB
Ended Awarded Last action
- Contract number
- SPE2DU26FEMNQ
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $125,593
Award facts
- Contract value 100% obligated
- $125,593.05 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order valued at $125,593.05 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. This delivery order, issued on December 1, 2025, with an ultimate completion date of December 2, 2025, falls under DMS Pharmaceutical Group's recently awarded Indefinite Delivery Contract (IDC) with a $499.999 billion ceiling under the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative. The PPV-G GEN V represents a $30.3 billion acquisition strategy designed to establish multiple regional prime vendor contractors to supply comprehensive pharmaceutical products and medical consumables to Department of Defense healthcare facilities worldwide. This delivery order was awarded without a set-aside designation, demonstrating DMS Pharmaceutical Group's competitive capability in unrestricted federal procurement.
DMS Pharmaceutical Group's product portfolio encompasses an extensive range of pharmaceuticals and medical consumables critical to military healthcare operations, including branded and generic prescription medications, over-the-counter drugs, biologics, vaccines, and specialty pharmaceuticals. The company supplies high-value specialty products such as oncology treatments (Keytruda, Tecentriq, Xtandi), immunosuppressants (Nucala, Xolair, Stelara, HEMLIBRA), emergency medications (epinephrine auto-injectors, naloxone), and routine pharmaceuticals spanning antibiotics, antivirals, and pain management drugs. As the sole awardee on this delivery order with no identified subcontractors, DMS Pharmaceutical Group will fulfill the pharmaceutical supply requirements specified under this order as part of its broader role as a critical pharmaceutical supplier supporting DLA's global military medical supply chain operations.
Quick answers
Who was awarded contract SPE2DU26FEMNQ?
SPE2DU26FEMNQ was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 1, 2025.
How much is contract SPE2DU26FEMNQ worth?
The government has obligated $125,593 on SPE2DU26FEMNQ.
Is contract SPE2DU26FEMNQ an order under another contract?
Yes. SPE2DU26FEMNQ is a delivery order under SPE2DU25D9517, an indefinite delivery contract.
Was contract SPE2DU26FEMNQ competed?
The extent of competition for SPE2DU26FEMNQ was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award